My elevator experience has given me an interesting new insight into the subject of alarm fatigue, questioning the response time difference between personal alerts and clinical, professional, or environmental ones. For me, it’s alarming.
Personal alerts vs. clinical alarms. Whether you work in the emergency department, an intensive care unit, or a med-surg unit, in an inpatient or outpatient setting, how often do you hear alarms on your shift?
Transcatheter Aortic Valve Replacement, (TAVR) offers provides an alternative for patients who aren’t candidates for surgical AVR. The author provides an overview of the procedure and patients’ needs.
Addressing Oral Health Needs of Patients with Diabetes
By Cynthia S. Darling-Fisher, PhD, FNP-BC; Wenche S. Borgnakke, DDS, MPH, PhD; and Judith Haber, PhD, APRN, BC, FAAN
Patients with diabetes have special needs for oral health assessment and care. The authors include a brief assessment tool that nurses can use to determine risk for periodontitis.
Find out what some of your colleagues have to say about ethics in nursing. At the June 2017 American Nurses Association (ANA) Membership Assembly in Washington DC, the Center for Ethics and Human Rights hosted a discussion with participants to assess the ethical climate of current nursing practice and determine needs across the nursing spectrum.
By Ashleigh Anderson, BSN, RN, PCCN, and Amanda Swedhin, BSN, RN, CMSRN
Implementing a Comfort Menu and Pain Cart to enhance use of nonpharmacologic pain management therapies among patients improved patient satisfaction scores.
As this nurse leader explains, communicating with compassion is always the best option. “Be kind whenever possible, and it is always possible.” For Rose Constantino, PhD, JD, RN, FAAN, FACFE, the 2016 recipient of ANA’s Jessie M. Scott Award, these words from the Dalai Lama are the ones she lives and leads by in her work as a teacher, researcher, advocate, and mentor.
Protecting American Families: Comprehensive Approach to Nicotine and Tobacco. Remarks by Scott Gottlieb, M.D. / Commissioner of Food and Drug Administration July 28, 2017 / White Oak, MD
Tobacco use remains the leading cause of preventable disease and death in the United States. But much has changed in the landscape of tobacco product regulation and FDA’s ability to address this public health crisis.
The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments.
This is the first FDA-approved therapy for the treatment of cGVHD.